Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325

British Journal of Pharmacology

Volumn 171, Issue 14, 2014, Pages 3511-3525

  Iijima, M ^a   Yoshimizu, T ^a   Shimazaki, T ^a   Tokugawa, K ^a   Fukumoto, K ^a   Kurosu, S ^a   Kuwada, T ^a   Sekiguchi, Y ^a   Chaki, Shigeyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

anxiety; arginine vasopressin; depression; HPA axis

Indexed keywords

1 [5 CHLORO 1 [(2,4 DIMETHOXYPHENYL)SULFONYL]] [3 (2 METHOXYPHENYL) 2 OXO 2,3 DIHYDRO 1H INDOL 3 YL] 4 FLUORO N,N DIMETHYL PROLINAMIDE; 2 [2 (3 CHLORO 4 FLUOROPHENYL)] 6 [[3 (MORPHOLIN 4 YL)PROPOXY] 4 OXOPYRIDO[2,3 D]PYRIMIDIN 3(4H) YL] N ISOPROPYLACETAMIDE; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DESMOPRESSIN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V1B RECEPTOR ANTAGONIST; 1-(5-CHLORO-1-((2,4-DIMETHOXYPHENYL)SULFONYL)-3-(2-METHOXYPHENYL)-2-OXO-2,3-DIHYDRO-1H-INDOL-3-YL)-4-FLUORO-N,N-DIMETHYLPROLINAMIDE; 2-(2-(3-CHLORO-4-FLUOROPHENYL)-6-(3-(MORPHOLIN-4-YL)PROPOXY)-4-OXOPYRIDO(2,3-D)PYRIMIDIN-3(4H)-YL)-N-ISOPROPYLACETAMIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; INDOLE DERIVATIVE; PROLINE; PYRIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; VASOPRESSIN RECEPTOR;

ADENOHYPOPHYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ELEVATED PLUS MAZE TEST; FORCED SWIM TEST; HYPERTHERMIA; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; NONHUMAN; OLFACTORY BULBECTOMY; PANIC; PRIORITY JOURNAL; RAT; SEPARATION-INDUCED ULTRASONIC VOCALIZATION TEST; SOCIAL INTERACTION; TRANQUILIZING ACTIVITY; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; CHO CELL LINE; CRICETULUS; DISEASE MODEL; HUMAN; METABOLISM; MOUSE; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; CHO CELLS; CORTICOSTERONE; CRICETULUS; DEPRESSION; DISEASE MODELS, ANIMAL; HUMANS; INDOLES; MALE; MICE; PROLINE; PYRIDINES; PYRIMIDINONES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, VASOPRESSIN;

EID: 84903128944     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12699     Document Type: Article

References (48)

1. Abelson JL, Le Melledo J, Bichet DG, (2001). Dose response of arginine vasopressin to the CCK-B agonist pentagastrin. Neuropsychopharmacology 24: 161-169.
2. Aguilera G, Rabadan-Diehl C, (2000). Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 96: 23-29.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
4. Antoni FA, (1984). Novel ligand specificity of pituitary vasopressin receptors in the rat. Neuroendocrinology 39: 186-188.
5. Appenrodt E, Kroning G, Schwarzberg H, (1999). Increased plasma ACTH in rats exposed to the elevated plus-maze is independent of the pineal gland. Psychoneuroendocrinology 24: 833-838.
6. Berkenbosch F, De Goeij DC, Tilders FJ, (1989). Hypoglycemia enhances turnover of corticotropin-releasing factor and of vasopressin in the zona externa of the rat median eminence. Endocrinology 125: 28-34.
7. Chaki S, Nakazato A, Kennis L, Nakamura M, Mackie C, Sugiura M, et al. (2004). Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur J Pharmacol 485: 145-158.
8. Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, et al. (2004). MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46: 457-467.
9. Chaviaras S, Mak P, Ralph D, Krishnan L, Broadbear JH, (2010). Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test. Psychopharmacology (Berl) 210: 35-43.
10. Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J, Thomson FJ, et al. (2008). Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res 170: 527-535.
11. File SE, Clarke A, (1980). Intraventricular ACTH reduces social interaction in male rats. Pharmacol Biochem Behav 12: 711-715.
12. Gorman JM, Papp LA, Coplan JD, Martinez JM, Lennon S, Goetz RR, et al. (1994). Anxiogenic effects of CO2 and hyperventilation in patients with panic disorder. Am J Psychiatry 151: 547-553.
13. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, et al. (2002). Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A 99: 6370-6375.
14. Griebel G, Simiand J, Stemmelin J, Gal CS, Steinberg R, (2003). The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Curr Drug Targets CNS Neurol Disord 2: 191-200.
15. Griebel G, Stemmelin J, Gal CS, Soubrie P, (2005). Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des 11: 1549-1559.
16. Griebel G, Beeské S, Stahl SM, (2012). The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 73: 1403-1411.
17. Griffante C, Green A, Curcuruto O, Haslam CP, Dickinson BA, Arban R, (2005). Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist. Br J Pharmacol 146: 744-751.
18. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, et al. (1997). Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 156: 766-775.
19. Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, Grigoriadis DE, (2002). Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27: 194-202.
20. Holsboer F, Haack D, Gerken A, Vecsei P, (1984). Plasma dexamethasone concentrations and differential suppression response of cortisol and corticosterone in depressives and controls. Biol Psychiatry 19: 281-291.
21. Iijima M, Chaki S, (2005). Separation-induced ultrasonic vocalization in rat pups: further pharmacological characterization. Pharmacol Biochem Behav 82: 652-657.
22. Iijima M, Chaki S, (2007). An arginine vasopressin V1b antagonist, SSR1494154 elicits antidepressant-like effects in an olfactory bulbectomy model. Prog Neuropsychopharmacol Biol Psychiatry 31: 622-627.
23. Iijima M, Ito A, Kurosu S, Chaki S, (2010). Pharmacological characterization of repeated corticosterone injection-induced depression model in rats. Brain Res 1359: 75-80.
24. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2011). Animal research: reporting in vivo experiments-the ARRIVE guidelines. J Cereb Blood Flow Metab 31: 991-993.
25. Liebowitz MR, Gorman JM, Fyer A, Dillon D, Levitt M, Klein DF, (1986). Possible mechanisms for lactate's induction of panic. Am J Psychiatry 143: 495-502.
26. Lolait SJ, O'Carroll AM, McBride OW, Konig M, Morel A, Brownstein MJ, (1992). Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357: 336-339.
27. Lolait SJ, O'Carroll AM, Mahan LC, Felder CC, Button DC, Young WS 3rd, et al. (1995). Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci U S A 92: 6783-6787.
28. van Londen L, Goekoop JG, van Kempen GM, Frankhuijzen-Sierevogel AC, Wiegant VM, van der Velde EA, et al. (1997). Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 17: 284-292.
29. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
30. Morel A, O'Carroll AM, Brownstein MJ, Lolait SJ, (1992). Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 356: 523-526.
31. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, et al. (1984). Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226: 1342-1344.
32. Olivier B, Molewijk HE, van der Heyden JA, van Oorschot R, Ronken E, Mos J, et al. (1998). Ultrasonic vocalizations in rat pups: effects of serotonergic ligands. Neurosci Biobehav Rev 23: 215-227.
33. Overstreet DH, Griebel G, (2005). Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharmacol Biochem Behav 82: 223-227.
34. Paxinos G, Watson C, (1986) The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press: Sydney, Australia.
35. Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF, (1996). Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 53: 137-143.
36. Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, et al. (2010). Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 58: 69-77.
37. Roy-Byrne PP, Uhde TW, Post RM, Gallucci W, Chrousos GP, Gold PW, (1986). The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry 143: 896-899.
38. Salome N, Stemmelin J, Cohen C, Griebel G, (2006). Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. Psychopharmacology (Berl) 187: 237-244.
39. Scott LV, Dinan TG, (1998). Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci 62: 1985-1998.
40. Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, et al. (2002). Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl) sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N, N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther 300: 1122-1130.
41. Shekhar A, Keim SR, (1997). The circumventricular organs form a potential neural pathway for lactate sensitivity: implications for panic disorder. J Neurosci 17: 9726-9735.
42. Shekhar A, Keim SR, Simon JR, McBride WJ, (1996). Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions. Pharmacol Biochem Behav 55: 249-256.
43. Shekhar A, Johnson PL, Fitz SD, Nakazato A, Chaki S, Steckler T, et al. (2011). A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses. Int J Neuropsychopharmacol 14: 355-365.
44. Shibata S, Nakanishi H, Watanabe S, Ueki S, (1984). Effects of chronic administration of antidepressants on mouse-killing behavior (muricide) in olfactory bulbectomized rats. Pharmacol Biochem Behav 21: 225-230.
45. Shimazaki T, Iijima M, Chaki S, (2006). The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats. Eur J Pharmacol 543: 63-67.
46. Spooren WP, Schoeffter P, Gasparini F, Kuhn R, Gentsch C, (2002). Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur J Pharmacol 435: 161-170.
47. Yamamoto T, Shibata S, Ueki S, (1982). Effects of locus coeruleus stimulation on muricide in olfactory bulbectomized and raphe lesioned rats. Jpn J Pharmacol 32: 845-853.
48. Zelena D, (2012). Vasopressin in health and disease with a focus on affective disorders. Cent Nerv Syst Agents Med Chem 12: 286-303.